VSDL Peptide Therapy for Acute Decompensated Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for congestive heart failure (CHF), particularly acute decompensated CHF, are limited in effectively alleviating symptoms and managing the condition, leading to frequent hospitalizations and high healthcare costs, with existing natriuretic treatments showing inferior benefits compared to the peptide VSDL.
Innovation Solution
Administration of a peptide derived from atrial natriuretic peptide (ANP) prohormone or its mimetic, specifically VSDL, to patients with CHF or ADCHF, via infusion at controlled rates to achieve beneficial haemodynamic, natriuretic, and diuretic effects while regulating plasma volume and blood pressure within clinically acceptable ranges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current monotherapeutic and polytherapeutic treatments are used for ADCHF, then treatment coverage is provided, but symptom alleviation is limited and hospitalization rates remain high
Solution Approach 1:
The invention segments the treatment approach by identifying and administering specific natriuretic peptides (ANP, BNP, CNP) and their mimetics as distinct therapeutic agents. This segmentation allows for targeted therapy that addresses specific pathophysiological mechanisms in ADCHF, improving treatment effectiveness while reducing the need for frequent hospitalizations compared to conventional non-specific therapies.
Solution Approach 2:
The invention applies parameter changes by administering natriuretic peptides at optimized doses and combinations that alter key physiological parameters including blood pressure, plasma volume, and renal function. These parameter changes produce clinically significant improvements in ADCHF symptoms and reduce hospitalization requirements, addressing both reliability and productivity concerns.
2Reliability
If higher doses of natriuretic peptides are administered, then haemodynamic effects are enhanced, but risk of adverse effects increases
Solution Approach 1:
The invention applies local quality by selecting specific natriuretic peptide types (ANP, BNP, CNP) and their mimetics that target particular physiological pathways. This localized approach allows for enhanced therapeutic benefits on specific haemodynamic parameters while minimizing broad-spectrum adverse effects that would occur with non-specific high-dose therapies.
Solution Approach 2:
The invention employs partial action by administering natriuretic peptides at doses that achieve sufficient therapeutic effect without reaching excessive levels that would cause adverse effects. The optimized dosing regimens produce the necessary haemodynamic changes while maintaining safety, resolving the contradiction between therapeutic benefit and adverse effects.
3Ease of operation
If traditional CHF treatments are used, then standard care is provided, but urine flow and sodium excretion are insufficient
Solution Approach 1:
The invention applies self-service by administering natriuretic peptides that activate the body's own natriuretic system, which naturally regulates fluid balance and blood pressure. This self-service mechanism enhances urine flow and sodium excretion through physiological pathways already present in the patient, making the treatment both accessible and highly effective without requiring complex external interventions.
Data Source
AI summary
The present invention relates to a method of treating congestive heart failure (CHF) in a subject comprising administering a peptide derived from atrial natriuretic peptide (ANP) prohormone (eg vessel dilator; VSDL) or a mimetic thereof. In a particular application, the invention provides a method of treating the particular indication known as acute decompensated congestive heart failure (ADCHF). Devices for intravenous or subcutaneous infusion for use in the method of the invention are also disclosed.